uniQure (QURE) just unveiled an update.
uniQure Inc. has entered into a significant asset purchase agreement with Genezen, where uniQure will sell its Lexington manufacturing facility and related operations. In return, uniQure will receive $25 million in a mix of preferred stock and a convertible note from Genezen. The deal, which includes employee transfers and executive board changes, is set to conclude in the third quarter of 2024, pending customary approvals. This strategic move also involves uniQure repaying $50 million of debt, and both companies entering into additional agreements post-transaction to ensure continued supply and development support for uniQure’s gene therapy programs.
For a thorough assessment of QURE stock, go to TipRanks’ Stock Analysis page.
